NuVasive Announces Investment in Novel Orthobiologic Company

SAN DIEGO, Jan. 13 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it has agreed to make an investment in Progentix Orthobiology BV, a Netherlands based company focused on developing novel orthobiologics.
This investment marks NuVasive's third strategic transaction in the biologics arena, amplifying the company's offering with a synthetic bone substitute technology that has the potential to compete with any biologic on the market today. Progentix is developing a synthetic bone substitute that is designed to accelerate bone healing through a novel micro-structure created by a proprietary manufacturing process.

Full text >> http://dialog.newsedge.com/portal.asp?site=2006120112282907013819&portlet=ep&searchfolderid=pg2006120112305702055933&action=sitetopics&block=portaldefault&related=off&searchid=2919&storyid=p0114814.0rw&rtcrdata=off